EUVIMEDEUVIMED entdecken
Crossref

CXCL13 variant predicts pegylated‐interferon α treatment response in HBeAg‐positive chronic hepatitis B patients

Mengqi Luo, Lingyan Zhang, Chou Yang, Bin Zhou, Jinlin Hou, De-Ke Jiang iD

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Mengqi Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Institutes of Liver Diseases Research of Guangd…. Hauptthemen laut MEDLINE: Chemokine CXCL13, Hepatitis B, Chronic, Interferon-alpha. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a key immune cytokine, C‐X‐C motif chemokine ligand 13 (CXCL13) has been reported to play critical roles in immune control of hepatitis B virus (HBV) infection. We aimed to screen single‐nucleotide polymorphisms (SNPs) of CXCL13 for predicting response to pegylated interferon‐alpha (PegIFNα) therapy of chronic hepatitis B (CHB) patients. Two independent cohorts with a total of 945 (Cohort 1, n = 238; Cohort 2, n = 707) hepatitis B e antigen (HBeAg)‐positive CHB patients treated with PegIFNα were enrolled in this retrospective cohort study. Eight candidate SNPs were selected through gene‐wide SNP mining within or flanking CXCL13 . A polygenic score (PGS) was utilized to assess the cumulative effects of multiple SNPs. The associations of candidate SNPs and PGS with combined response (CR, defined as the combination of HBeAg seroconversion and HBV DNA level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CXCL13Hepatitis B, ChronicInterferon-alphaHumansAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusPolyethylene GlycolsRecombinant ProteinsRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

C-X-C motif chemokine ligand 13 (CXCL13)chronic hepatitis B (CHB)hepatitis B virus (HBV)pegylated interferon-alpha (PegIFNα)single-nucleotide polymorphism (SNP)

Substanzen

Antiviral AgentsChemokine CXCL13CXCL13 protein, humanHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsRecombinant Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Institutes of Liver Diseases Research of Guangdong Province, Department of Infectious Diseases and Hepatology Unit, N…
  • The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.

ORCID-Profile: De-Ke Jiang

Zitieren

APA

Luo, M., Zhang, L., Yang, C., Zhou, B., Hou, J., & Jiang, D. K. (2023). CXCL13 variant predicts pegylated‐interferon α treatment response in HBeAg‐positive chronic hepatitis B patients. Journal of Medical Virology. https://doi.org/10.1002/jmv.28963

Vancouver

Luo M, Zhang L, Yang C, Zhou B, Hou J, Jiang DK. CXCL13 variant predicts pegylated‐interferon α treatment response in HBeAg‐positive chronic hepatitis B patients. Journal of Medical Virology. 2023. doi:10.1002/jmv.28963

BibTeX
@article{Luo2023,
  author = {Luo, Mengqi and Zhang, Lingyan and Yang, Chou and Zhou, Bin and Hou, Jinlin and Jiang, De-Ke},
  title = {CXCL13 variant predicts pegylated‐interferon α treatment response in HBeAg‐positive chronic hepatitis B patients},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28963}
}
Kostenlos starten →